SECURITIES AND EXCHANGE COMMISSION ~~Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act~~

~~June 30~~WASHINGTON, ~~2006~~DC 20549

~~Date~~FORM ~~of Report~~8-K

~~(Date~~Current ofReport ~~earliest event reported)~~Pursuant

~~Syntony~~to ~~Group,~~Section ~~Inc.~~13 or 15(d) of the

~~(Exact~~Securities ~~name~~Exchange Act of ~~registrant as specified in its charter)~~1934

~~Utah (State~~Date of ~~Incorporation)~~Report: ~~000-50678 (Commission~~May ~~File~~16, ~~Number) 87-0369068 (IRS Employer Identification No.)~~ 2008

PULMO BIOTECH INC.

(Exact name of Registrant as specified in charter)

Delaware	000-50678	20-5622985

(State or other jurisdiction of incorporation)	(Commission File No.)	(I.R.S. Employer Identification No.)

1035 Park Avenue, Suite 7B

New York, ~~New~~NY ~~York~~ 10028-0912

(Address of Principal Executive Offices)

(646) 827~~-9362~~ ~~(Registrant's Telephone Number)~~9362

~~N/A~~(Registrant's telephone number, including area code)

~~(Former~~Item ~~Name~~7.01. orRegulation ~~Former~~FD ~~Address if changed Since Last Report)~~Disclosure.

~~Check~~On ~~the~~May ~~appropriate~~16, ~~box~~2008, ~~below~~Pulmo ifBioTech ~~the~~Inc., ~~Form~~a ~~8-K~~Delaware ~~filing~~corporation, isreleased ~~intended~~a topress ~~simultaneously~~release ~~satisfy~~in ~~the~~which ~~filing~~it announced ~~obligation~~the details of the ~~Registrant~~methodology ~~under~~for ~~any~~the Phase 1 human trials for its PulmoBind molecular imaging product candidate. A copy of the ~~following~~release ~~provisions~~is ~~(see~~attached ~~general~~hereto ~~instruction~~as ~~A.2.~~Exhibit ~~below):~~99.1

[Item ~~] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230~~9.~~425)~~01
. Financial Statements and Exhibits

~~[ ] Soliciting material pursuant to Rule 14-~~(a~~-12~~) ~~under~~Financial ~~the~~Statements ~~Exchange~~of ~~Act~~Businesses ~~(17 CFR 240~~Acquired.~~14a-12)~~ N/A

~~[ ] Pre-commencement communications pursuant to Rule 14d-2~~(b) ~~under~~Pro ~~the~~Forma ~~Exchange~~Financial ~~Act (17 CFR 240~~Information.~~14d-2(b))~~
N/A

~~[ ] Pre-commencement communications pursuant to Rule 13e-4~~(c) ~~under~~Shell ~~the~~Company ~~Exchange Act (17 CFR 240.13e-4(c))~~Transactions
. N/A

~~Item 1.01 Entry into a Material Definitive Agreement.~~(d)
Exhibits

~~On June 30, 2006, Syntony Group, Inc~~ 99.,1. aPress ~~Utah~~Release ~~corporation~~dated May ~~(the “Company”)~~16, filed an Information Statement on Schedule 14f-1 (the “Information Statement”) with the Securities Exchange Commission (the “Commission”)and mailed a copy of the Information Statement to its shareholders pursuant to Section 14(f) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 14f-1 thereunder2008.

Effective June 30, 2006, Michael Vardakis, the principal shareholder of the Company (“Vardakis”), entered into a Stock Purchase Agreement (the “Agreement”) with David Price (“Price”), pursuant to which, among other things, Vardakis agreed to sell to Price and Price agreed to purchase from Vardakis, 12,345,001 shares of Common Stock, par value $.0001 per share (“Common Stock”), of the Company owned of record and beneficially by Vardakis (the “Purchased Shares”). Price is an “accredited investor” as such term is defined in Rule 501 of Regulation D promulgated by the Commission under the Securities Act of 1933 (the “Securities Act”). The aggregate purchase price for the Purchased Shares is $600,000, or approximately $.0486 per share. The Purchased Shares represent approximately 90.0% of the 13,723,462 issued and outstanding shares of Common Stock. Pursuant to the Agreement, Price assigned his rights and obligations with respect to the Purchased Shares as follows: 12,325,001 shares to Tendall FZCO, a Dubai Free Zone corporation (“Tendall”) of which Price is the sole record and beneficial owner, 10,000 shares to Alain V Vitterli, ("Vitterli"), 5,000 shares to Ian Ilsley ("Ilsley") and 5,000 shares to Robert Lawrence Banner ("Banner"). Each of Price, Tendall, Vitterli, Ilsley and Banner is an accredited investor. Tendall used its working capital and Vitterli, Ilsley and Banner used their personal funds to purchase the Purchased Shares on June 30, 2006.SIGNATURES

~~Effective~~Pursuant ~~June 30, 2006, Vardakis also entered into and Installment Purchase Agreement (the “Installment Agreement”) with Price, pursuant~~ to ~~which, among other things, Vardakis agreed to sell to Price and Price agreed to purchase from Vardakis, an additional 600,000 shares of Common Stock of~~ the ~~Company~~requirements ~~owned~~ of ~~record and beneficially by Vardakis (~~the ~~“Installment~~Securities ~~Shares”). The~~Exchange ~~aggregate purchase price for the Installment Shares is $300,000, or $.50 per share. The Installment Shares represent approximately 4.4%~~ Act of ~~the 13~~1934,~~723,462~~ ~~issued and outstanding shares of Common Stock. The Installment Agreement provides that~~ the ~~purchase~~registrant ~~price~~has ~~for~~duly ~~the~~caused ~~Installment~~this ~~Shares~~report ~~will~~to be ~~paid~~signed ~~in 12 consecutive monthly installments, without interest, commencing~~ on October 31, 2006, and on the last day of each month thereafter through and including September 30, 2007. If any such date is not a business day, the installment will be due on the following business day. Pursuant to the Installment Agreement, Price assigned his rights and obligations with respect to the Installment Shares to Jockey Holding LTD, a British West Indies corporation (“Jockey”). Jockey is an accredited investor and will use its ~~working~~ capital to purchase the Installment Shares. Pursuant to the Installment Agreement: (i) Vardakis has deposited with Hirshfield Law, as Escrow Agent (the “Escrow Agent”), under an Escrow Agreement dated as of June 30, 2006 (the “Escrow Agreement”) between Vardakis, Price and the Escrow Agent, 300,000 additional shares of Common Stock owned of record and beneficially behalf by ~~Vardakis to ensure Vardakis' performance under~~ the ~~Installment~~undersigned ~~Agreement;~~hereunto ~~and~~duly ~~(ii) Price has deposited with the Escrow Agent 2,000,000 of the Purchased Shares to ensure the performance of Jockey under the Installment Agreement~~authorized.

Pursuant to the Agreement, on June 30, 2006: (i) the Company's Board of directors was increased from two members, Vardakis and Matthew C. Lords (“Lords”), to four members by adding Ilsley and Vetterli; (ii) Vardakis and Lord resigned as officers of the Company; and (iii) Vetterli was elected as the Chief Executive Office, Chief Financial Officer and Secretary. Information concerning the officers and directors of the Company is incorporated into this Report by reference to the “Directors and Executive Officers” section of the Information Statement pursuant to Rule 12b-23 (“Rule 12b-23”) promulgated by the Commission under the Exchange Act.

	PULMO BIOTECH INC.
Date: May 16, 2008	By: /s/ Garry McCann.
	Name: Garry McCann
	Title: President and Chief Executive Officer

The Information Statement describes under the caption “Security Ownership of Certain Beneficial Owners and Management” the security ownership of each person who was, prior to June 30, 2006, the beneficial owner of more than 5% of the Company's 13,723,462 outstanding shares of Common Stock and each officer and director of the Company. The information under that caption of the Information Statement is incorporated into this Report by reference pursuant to Rule 12b-23.

The foregoing description of the Agreement, the Installment Agreement and the Escrow Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement, the Installment Agreement and the Escrow Agreement which are filed as Exhibit 10.1, 10.2 and 10.3 hereto, respectively, and are incorporated into this Report pursuant to Rule 12b-23.

Item 5.01 Changes in Control of Registrant.

The Information Statement describes the change in control of the Company that has occurred pursuant to the Agreement and the Installment Agreement. The information under the caption “Changes in Control” in the Information Statement is incorporated into this Report by reference pursuant to Rule 12b-23.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Description of Exhibit	Exhibit Number
Purchase Agreement dated as of June 30, 2006 between Michael Vardakis and David Price	10.1
Installment Agreement dated as of June 30, 2006 between Michael Vardakis and David Price	10.2
Escrow Agreement dated as of June 30, 2006 among Michael Vardakis, David Price and Hirshfield Law, as Escrow Agent	10.3
Information Statement mailed to the shareholders of the Company on June 30, 2006 pursuant to Section 14(f) of the Exchange Act and Rule 14f-1 thereunder	20.1

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

SYNTONY GROUP, INC. Dated: 07/07/2006 /s/ Alain U. Vetterli Chief Executive Officer, Chief Financial Officer, Secretary and Director

Exhibit Index

Description of Exhibit	Exhibit Number
Purchase Agreement dated as of June 30, 2006 between Michael Vardakis and David Price	10.1
Installment Agreement dated as of June 30, 2006 between Michael Vardakis and David Price	10.2
Escrow Agreement dated as of June 30, 2006 among Michael Vardakis, David Price and Hirshfield Law, as Escrow Agent	10.3
Information Statement mailed to the shareholders of the Company on June 30, 2006 pursuant to Section 14(f) of the Exchange Act and Rule 14f-1 thereunder	20.1

Filing Compare · PULMO BIOTECH INC.